Yaolin Xu

Dr. Yaolin Xu

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
HZHua Zhang
Hua Zhang
LZLin Zhao
Lin Zhao
JJJingjing Jiang
Jingjing Jiang
JZJie Zheng
Jie Zheng
LYLi Yang
Li Yang
XDXiangfeng Duan
Xiangfeng Duan
As cancer is increasingly considered a metabolic disorder, it is postulated that serum metabolite profiling can be a viable approach for detecting the presence of cancer. By multiplexing mass spectrometry fingerprints from two independent nanostructured matrixes through machine learning for highly sensitive detection and high throughput analysis, we report a laser desorption/ionization (LDI) mass spectrometry-based liquid biopsy for pan-cancer screening and classification. The Multiplexed Nanomaterial-Assisted LDI for Cancer Identification (MNALCI) is applied in 1,183 individuals that include 233 healthy controls and 950 patients with liver, lung, pancreatic, colorectal, gastric, thyroid cancers from two independent cohorts. MNALCI demonstrates 93% sensitivity at 91% specificity for distinguishing cancers from healthy controls in the internal validation cohort, and 84% sensitivity at 84% specificity in the external validation cohort, with up to eight metabolite biomarkers identified. In addition, across those six different cancers, the overall accuracy for identifying the tumor tissue of origin is 92% in the internal validation cohort and 85% in the external validation cohort. The excellent accuracy and minimum sample consumption make the high throughput assay a promising solution for non-invasive cancer diagnosis.

28 January 2021 in Cell Cycle
Verified
Journal Article
Closed access
XHXu Han
Xu Han
YFYuan Fang
Yuan Fang
PCPingping Chen
Pingping Chen
YXYaolin Xu
Yaolin Xu
WZWentao Zhou
Wentao Zhou
WLWenhui Lou
Wenhui Lou
Circular RNAs (circRNAs), the new stars of endogenous non-coding RNAs, are dysregulated in various tumors including pancreatic cancer. Here, we aimed to investigate the biological functions of hsa_circ_0071036 in the tumourigenesis and progression of pancreatic ductal adenocarcinoma (PDAC) and its clinical implications. The differential expression profile of circRNAs in 4 pairs of PDAC tissues was analyzed by microarray assay. Quantitative real-time PCR and fluorescence in situ hybridization (FISH) were utilized to determine the expression patterns and their clinical significance. Functional experiments in vitro and in vivo were performed to explore whether hsa_circ_0071036 functions as an oncogenic circRNA in PDAC. Mechanistically, RT-qPCR, dual luciferase reporter and RNA pull-down assays were conducted to identify the interaction between hsa_circ_0071036 and miR-489 in PDAC. Hsa_circ_0071036 was remarkably overexpressed in PDAC cell lines and tissue samples, which negatively correlated with miR-489 expression. Aberrant expression of hsa_circ_0071036 correlated with poor clinicopathological characteristics and prognoses of PDAC patients. Knockdown of hsa_circ_0071036 suppressed proliferation and invasion and induced apoptosis in vitro. Moreover, the in vivo xenograft model confirmed that silencing of hsa_circ_0071036 attenuated tumor growth. Mechanistic analyses indicated that hsa_circ_0071036 acted as an efficient miRNA sponge for miR-489 in PDAC. In summary, our study revealed that upregulated hsa_circ_0071036 promotes PDAC pathogenesis and progression by directly sponging miR-489, which implies an important role for this circRNA-miRNA functional network.

18 January 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ZZZheng Zhang
Zheng Zhang
HXHuaxiang Xu
Huaxiang Xu
JHJunyi He
Junyi He
QHQiangsheng Hu
Qiangsheng Hu
YLYuxin Liu
Yuxin Liu
LLLiang Liu
Liang Liu
As a novel form of nonapoptotic cell death, ferroptosis is developing into a promising therapeutic target of dedifferentiating and therapy-refractory cancers. However, its application in pancreatic cancer is still unknown. In the preliminary research, we found that F-box and WD repeat domain-containing 7 (FBW7) inhibited the migration and proliferation of pancreatic cancer cells through its substrate c-Myc. We further found that another key substrate of FBW7, KLF5, could inhibit ferroptosis. Inhibiting KLF5 significantly enhances the cytotoxicity of oxaliplatin rather than other chemotherapy drugs. Mechanistically, we found that KLF5 inhibited the expression of heme oxygenase 1 (HMOX1) via repressing zinc finger E-box-binding homeobox 1 (ZEB1). Inhibition of KLF5 facilitated the cytotoxic effect of oxaliplatin via promoting ferroptosis. Oxaliplatin combined with KLF5 inhibitor significantly potentiated cell death in vitro and inhibited tumor growth in vivo compared with either treatment alone. These results reveal a critical role of KLF5 in sensitized chemotherapy of pancreatic cancer, and suggest that ferroptosis combined with platinum-based chemotherapy rather than gemcitabine-based chemotherapy is expected to bring better therapeutic effects.

28 April 2018 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
YXYaolin Xu
Yaolin Xu
XGXi Guo
Xi Guo
YFYue Fan
Yue Fan
DWDansong Wang
Dansong Wang
WWWenchuan Wu
Wenchuan Wu
YZYu-Hong Zhou
Yu-Hong Zhou
To compare efficacy and safety of nabpaclitaxel plus S-1 (AS) with gemcitabine plus S-1 (GS) as first-line treatment for metastatic pancreatic cancer. We conducted a retrospective cohort, single-institution analysis by reviewing medical records of 38 patients who received either AS (nabpaclitaxel 125 mg/m2 on Days 1, 8 and S-1 80 mg/m2 on Days 1 to 14) or GS (gemcitabine 1000 mg/m2 on Days 1, 8 and S-1 80 mg/m2 on Days 1 to 14) chemotherapy. AS was associated with a prolonged median time to progression (TTP; 7.1 months, 95% CI, 4.5–9.7 vs. 3.6 months, 95% CI, 1.8–5.4; P value = 0.022) and improved median overall survival (OS; 10.2 months, 95% CI, 9.1–11.3 vs. 6 months, 95% CI, 4.2–7.8; P value <0.001) compared with GS. In cox proportional hazards model, treatment regimen was the only variable to be significantly associated with improvements in both TTP and OS. Subgroup analyses based on HER2 expression showed that AS seemed to have better outcome of OS in HER2 positive patients (HR = 0.168; 95% CI, 0.022–1.27; P value = 0.084). Hematological adverse events were commonly seen in both group (12.5% and 22.7%, GS and AS group, Grade 3 or 4; P value = 0.675) while AS got increased risk of sensory neuropathy (6 of 22 patients in AS, 27.3% vs. 0 of 16 patients in GS, all grade; P value = 0.03). AS could be an effective treatment regimen for metastatic pancreatic cancer under surveillance of toxicity.

28 June 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
CSChao Song
Chao Song
GWGanggang Wang
Ganggang Wang
MLMengmeng Liu
Mengmeng Liu
SHSiyang Han
Siyang Han
MDMeiyuan Dong
Meiyuan Dong
LLLiang Liu
Liang Liu
Objective: This study aims to elucidate the functional role of IQGAP1 phosphorylation modification mediated by the SOX4/MAPK1 regulatory axis in developing pancreatic cancer through phosphoproteomics analysis. Methods: Proteomics and phosphoproteomics data of pancreatic cancer were obtained from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) database. Differential analysis, kinase-substrate enrichment analysis (KSEA), and independent prognosis analysis were performed on these datasets. Subtype analysis of pancreatic cancer patients was conducted based on the expression of prognostic-related proteins, and the prognosis of different subtypes was evaluated through prognosis analysis. Differential analysis of proteins in different subtypes was performed to identify differential proteins in the high-risk subtype. Clinical correlation analysis was conducted based on the expression of prognostic-related proteins, pancreatic cancer typing results, and clinical characteristics in the pancreatic cancer proteomics dataset. Functional pathway enrichment analysis was performed using GSEA/GO/KEGG, and most module proteins correlated with pancreatic cancer were selected using WGCNA analysis. In cell experiments, pancreatic cancer cells were grouped, and the expression levels of SOX4, MAPK1, and the phosphorylation level of IQGAP1 were detected by RT-qPCR and Western blot experiments. The effect of SOX4 on MAPK1 promoter transcriptional activity was assessed using a dual-luciferase assay, and the enrichment of SOX4 on the MAPK1 promoter was examined using a ChIP assay. The proliferation, migration, and invasion functions of grouped pancreatic cancer cells were assessed using CCK-8, colony formation, and Transwell assays. In animal experiments, the impact of SOX4 on tumor growth and metastasis through the regulation of MAPK1-IQGAP1 phosphorylation modification was studied by constructing subcutaneous and orthotopic pancreatic cancer xenograft models, as well as a liver metastasis model in nude mice. Results: Phosphoproteomics and proteomics data analysis revealed that the kinase MAPK1 may play an important role in pancreatic cancer progression by promoting IQGAP1 phosphorylation modification. Proteomics analysis classified pancreatic cancer patients into two subtypes, C1 and C2, where the high-risk C2 subtype was associated with poor prognosis, malignant tumor typing, and enriched tumor-related pathways. SOX4 may promote the occurrence of the high-risk C2 subtype of pancreatic cancer by regulating MAPK1-IQGAP1 phosphorylation modification. In vitro cell experiments confirmed that SOX4 promoted IQGAP1 phosphorylation modification by activating MAPK1 transcription while silencing SOX4 inhibited the proliferation, migration, and invasion of pancreatic cancer cells by reducing the phosphorylation level of MAPK1-IQGAP1. In vivo, animal experiments further confirmed that silencing SOX4 suppressed the growth and metastasis of pancreatic cancer by reducing the phosphorylation level of MAPK1-IQGAP1. Conclusion: The findings of this study suggest that SOX4 promotes the phosphorylation modification of IQGAP1 by activating MAPK1 transcription, thereby facilitating the growth and metastasis of pancreatic cancer.

1 February 2024 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
CSChao Song
Chao Song
MLMengmeng Liu
Mengmeng Liu
GWGanggang Wang
Ganggang Wang
ZXZijin Xu
Zijin Xu
SHSiyang Han
Siyang Han
JHJunyi He
Junyi He
Background: Gastric cancer (GC) is a common tumors in the digestive tract, and effective treatment methods are still lacking. Bone morphogenetic protein 6 (BMP6) is closely related to the occurrence and development of various tumors, but its relevance to GC is still unclear. The aim of the study was to explore the relationship between BMP6 and the occurrence and development of GC. Methods: In this study, we investigated the relationship between BMP6 and the prognosis of GC patients using bioinformatics technology and clinical tissue samples. We also explored the connection between BMP6 and the biological behavior of GC cells through molecular biology experiments and relevant in vivo animal experiments. Finally, we examined the mechanisms by which BMP6 inhibits the onset and progression of GC. Results: Through analysis of The Cancer Genomics Atlas (TCGA) database, we observed that BMP6 is expressed at low levels in GC, and its low expression is associated with a poor prognosis in GC patients. Cell experiments demonstrated that BMP6 expression can influence the proliferation of GC cells both in vitro and in vivo. Furthermore, we discovered that BMP6 is linked to the nuclear factor-κB (NF-κB) pathway, and subsequent experiments confirmed that BMP6 can inhibit the biological activity of GC cells by activating the NF-κB pathway. Conclusions: Our findings suggest that BMP6 is a potential prognostic biomarker in GC and can regulate the biological activity of GC cells through the NF-κB pathway. BMP6 may serve as a promising therapeutic target for GC, and our study introduces novel ideas for the prevention and treatment of this disease.